Financial Data and Key Metrics Changes - In FY 2025, the company achieved record revenue of $21.8 billion, representing a growth of 7.7% adjusted for foreign exchange and 2.9% organic growth [4] - Adjusted gross margin increased by 140 basis points, contributing to an 80 basis points expansion in adjusted operating margin, resulting in a record 25% adjusted operating margin [5][7] - Adjusted diluted EPS grew by 9.6%, inclusive of tariffs, while the company returned $2.2 billion to shareholders, including a $1 billion share buyback [5] Business Line Data and Key Metrics Changes - New BD delivered organic revenue growth of 3.9%, with solid growth across key platforms [4] - The company launched over 125 new products and added $1.3 billion through more than 20 accretive high-growth tuck-in acquisitions [6] Market Data and Key Metrics Changes - The company navigated a dynamic market environment, including changes in research spending, vaccine utilization, tariffs, and ongoing geopolitical uncertainty [7] - The agreement to combine the Biosciences and Diagnostic Solutions business with Waters Corp is expected to create a life science and diagnostics leader, enhancing growth opportunities [8] Company Strategy and Development Direction - The company is transitioning to a new growth strategy called "Excellence Unleashed," focusing on three strategic priorities: compete, innovate, and deliver [9] - The capital allocation framework prioritizes share repurchases, reliable and increasing dividends, and focused tuck-in M&A in high-growth markets [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute on the new growth strategy and emphasized the importance of operational excellence for reinvestment in commercial and innovation capabilities [9][10] - The company aims to maximize its platforms for faster long-term growth, building on the advancements made over the last five years [10] Other Important Information - The company announced its 54th consecutive year of dividend increases, reflecting the consistency and reliability of its dividend policy [5] - The transaction with Waters Corp is expected to close on February 9, subject to customary closing conditions [8] Q&A Session Summary Question: Were there any questions from shareholders? - There were no questions received during the Q&A session [14]

Group 1 - The core focus of the "Beijing Action Plan for Supporting the Development of Artificial Intelligence Applications in the Medical and Health Sector (2026-2027)" is on enhancing clinical diagnosis, grassroots health, and health management, while also expanding into public health management, intelligent management of medical institutions, industry regulation, and public-facing intelligent services [1] - The plan emphasizes the importance of not allowing artificial intelligence to completely replace the professional judgment of medical personnel, ensuring the rationality of medical decisions and humanistic care [1] - The plan aims to establish a governance system covering the entire data lifecycle and to create unified standards and norms for data generation, collection, aggregation, storage, and application [3] Group 2 - The plan encourages collaboration between medical institutions and high-quality AI companies for application research and development, promoting mature products across relevant medical institutions in the city [3] - The "Several Measures" document further proposes "medical-enterprise collaboration," highlighting the necessity of professional medical knowledge for data annotation and model validation [3][5] - The use of blockchain technology is proposed to create a trusted data space for healthcare, enabling model training in a secure environment and facilitating the conversion of data resources into economic value [7] Group 3 - Various levels of medical institutions in Beijing are applying AI products tailored to their specific needs, with examples including AI services in pre-hospital, in-hospital, and post-discharge follow-up processes [6] - AI technology is being promoted in grassroots medical institutions, with applications such as AI retinal imaging and pre-prescription review systems [6] - The collaboration among enterprises in the medical AI sector is deemed essential for sharing mature technologies and algorithms, thereby avoiding resource duplication and collectively advancing the industry [5]

Core Insights - Festi's Q3 2025 performance exceeded expectations, confirming operational strength and momentum across subsidiaries [2][3][7] Financial Performance - Sales of goods and services reached ISK 47,093 million, a 6.4% year-over-year increase, and a 9.1% increase when excluding currency and fuel price effects [3] - Margin from sales amounted to ISK 12,057 million, reflecting an 11.3% increase from the previous year [3] - Profit margin improved to 25.6%, up by 1.1 percentage points from Q3 2024, with a 0.5 percentage point increase when excluding currency and fuel price effects [3] - EBITDA for the quarter was ISK 5,319 million, a 12.2% increase year-over-year [3] - Profit for the quarter was ISK 2,651 million, an 18.8% increase compared to the previous year [3] - Net cash from operating activities increased by 43.5% to ISK 6,664 million [3] - Equity at the end of Q3 2025 was ISK 46,097 million, with an equity ratio of 39.2% [3] Strategic Developments - Festi raised its EBITDA guidance for 2025 by ISK 400 million, now projected between ISK 15,600 million and ISK 16,000 million [3] - ELKO launched ELKO Smart Payments, allowing customers to spread payments flexibly, and plans to introduce a digital advisor powered by AI [4][5] - Krónan opened a new flagship store and plans to expand its store network further [4] - N1 introduced fast-charging for electric vehicles, receiving positive customer feedback [4] - A new refrigerated warehouse is set to open in Q1 2026 to enhance internal efficiency [4] Market Outlook - Despite macroeconomic uncertainties, Festi's outlook remains strong, with a focus on customer service and sustainable products [6][7] - Potential challenges include the impact of recent Supreme Court rulings on interest rates and reduced fishing quotas affecting key export industries [6]

Group 1 - The manufacturing industry in Guangdong is experiencing a significant transformation driven by intelligent industrial robots, which are capable of various tasks such as assembly, loading, and welding, as well as autonomous collaboration using AI technology [1] - Guangdong has become the largest industrial robot market globally, with continuous growth expected due to ongoing technological advancements and the expansion of application scenarios [1] - In the first five months of this year, Guangdong's industrial robot production reached 124,700 units, marking a year-on-year increase of 33% [2] Group 2 - KUKA robots are being utilized across various industries, including automotive manufacturing, lithium battery production, photovoltaic sectors, and healthcare, indicating a broad application of industrial robots [2] - The Guangdong government has launched the first batch of "robot+" application scenarios, covering 11 key areas, to enhance production efficiency and improve quality of life [2] - The complexity of manufacturing scenarios is increasing, necessitating the development of more advanced software systems to enable collaborative production between humans and robots [3] Group 3 - The integration of AI with robotics is expected to enhance the capabilities of robots, allowing for intelligent decision-making and adaptability in complex manufacturing environments [3] - The Guangdong government aims to accelerate the commercialization of AI and robotics technologies, promoting deeper integration of these technologies across various industries [4]